ArticleScience translational medicine2025
Immunopeptidomics can inform the design of mRNA vaccines for the delivery of
Abstract read
In one paragraph
Article in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Host-pathogen interactions in tuberculosis: from immunological mechanisms to translational applications.Cell insight · 2026Review
- Immunopeptidomics reveals conserved and abundant Francisella tularensis proteins as immunogenic CD4 T cell antigens in mice.PLoS pathogens · 2026Article
- Monocytic niches escape T cell surveillance and promote Mycobacterium tuberculosis persistence in lymph nodes.Immunity · 2026Article
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
- A Platform for High-throughput and Ultrasensitive Immunopeptidomics.Molecular & cellular proteomics : MCP · 2026Article
- mRNA vaccine development for tuberculosis: antigen design, immune mechanisms, and translational challenges.Archives of microbiology · 2026Review
- Rare variable M. tuberculosis antigens induce predominant Th17 responses in human infection.JCI insight · 2026Article
- Immunopeptidomics of cutaneous leishmaniasis patients reveals the natural antigenic landscape.Frontiers in immunology · 2026Article
- Exhausted CD4Frontiers in immunology · 2026Article
- Human CD4+ T cells recognize Mycobacterium tuberculosis-infected macrophages amid broader responses.The Journal of experimental medicine · 2025Article
Corrections and comments
- Update of
Authors and funding
15 authors.
Owen LeddyDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-3437-1956
Paul OgongoDivision of Experimental Medicine, University of California, San Francisco, CA 94110, USA.ORCID 0000-0002-0093-5768
Julia HuffakerDivision of Experimental Medicine, University of California, San Francisco, CA 94110, USA.ORCID 0009-0008-8939-1971
Mingyu GanDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Ryan MilliganRagon Institute of Mass General, Harvard, and MIT, Cambridge, MA 02139, USA.ORCID 0009-0007-7695-5101
Sheikh MahmudDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0009-0006-6063-7259
Heyuan Michael NiDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-0881-7245
Yuko YukiMycobacterial Disease Research Directorate, Armauer Hansen Research Institute, Addis Ababa 10005, Ethiopia.ORCID 0000-0003-1721-6003
Kidist BoboshaMycobacterial Disease Research Directorate, Armauer Hansen Research Institute, Addis Ababa 10005, Ethiopia.ORCID 0000-0001-8091-7182
Liya WassieMycobacterial Disease Research Directorate, Armauer Hansen Research Institute, Addis Ababa 10005, Ethiopia.ORCID 0000-0002-5494-5275
Mary CarringtonRagon Institute of Mass General, Harvard, and MIT, Cambridge, MA 02139, USA.ORCID 0000-0002-2692-2180
Qingyun LiuDepartment of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-2284-5050
Joel D ErnstDivision of Experimental Medicine, University of California, San Francisco, CA 94110, USA.ORCID 0000-0001-9951-6207
Forest M WhiteDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-1545-1651
Bryan D BrysonDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-1716-6712
Funding
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4MRole of antigen-specific T cell responses in the control of TBU19AI111211 · NIAID · EMORY UNIVERSITY · PI BLUMBERG, HENRY M, ERNST, JOEL D. · 2014 to 2020
$20.1MTRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1MQuantitative systems biology of glioblastoma cells and their interactions with the neuronal and immunological milieuU54CA283114 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Forest M White · 2023 to 2026
$9.7MEthiopia-Emory TB Research Training ProgramD43TW009127 · FIC · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Kidist Bobosha · 2013 to 2026
$3.4MFunctionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigensR01AI173002 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joel D. Ernst · 2023 to 2026
$3.4MHigh-dimensional characterization of phagosome composition, control and phagocytic receptor redundancyR35GM142900 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI BRYSON, BRYAN DAVID · 2021 to 2025
$2.1MIdentification of adaptive response mechanisms in breast cancer by information theory and proteomicsU01CA238720 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KRAVCHENKO-BALASHA, NATALY, WHITE, FOREST M · 2019 to 2023
$2.0MFIC NIH HHS D43 TW009127NCI NIH HHS U01 CA238720NCI NIH HHS U54 CA283114NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI173002NIAID NIH HHS U19 AI111211NIEHS NIH HHS T32 ES007020NIGMS NIH HHS R35 GM142900
Abstract
No currently licensed vaccine reliably prevents pulmonary tuberculosis (TB), a leading cause of infectious disease mortality. Developing effective new vaccines requires identifying which
Indexed as
Antigens, BacterialHistocompatibility Antigens Class IImRNA VaccinesMycobacterium tuberculosisPeptidesTuberculosis VaccinesAntigen PresentationHumansMass SpectrometryPhagocytesAntigens, BacterialHistocompatibility Antigens Class IImRNA VaccinesPeptidesTuberculosis Vaccines
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.